VPC-70063

• Description:

  VPC-70063 is a potent Myc-Max inhibitor with an IC50 value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; c-Myc; PARP

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vpc-70063.html

• Purity:

  99.92

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  FC (F) (C1=CC (NC (NCC2=CC=CC=C2) =S) =CC (C (F) (F) F) =C1) F

• Molecular Formula:

  C16H12F6N2S

• Molecular Weight:

  378.34

• References & Citations:

  [1]Carabet LA, et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem. 2018 Dec 5;160:108-119.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  13571-44-3